Overview

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Status:
Completed
Trial end date:
2021-05-25
Target enrollment:
Participant gender:
Summary
The purpose of Part 1 of the study is to determine the safety and efficacy of topical ocular ECF843 compared to topical ocular vehicle for the relief of the signs and symptoms associated with moderate to severe dry eye disease (DED). Part 2 of the study is exploratory only and intended to explore potential areas of differentiation between ECF843 and topical ocular vehicle for the treatment of subjects with dry eye disease.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Lifitegrast